在血液透析治疗的血清学无应答者中，HBV 疫苗接种后产生 HBsAg 反应性 T 细胞和 B 细胞。
Generation of HBsAg-reactive T- and B-cells following HBV vaccination in serological non-responders under hemodialysis treatment.
机构信息
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.
Center for Translational Medicine, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
出版信息
Eur J Immunol. 2021 May;51(5):1278-1281. doi: 10.1002/eji.202048756. Epub 2021 Feb 9.
HBV vaccination is recommend for hemodialysis patients, but only 50-60% of the patients show seroconversion. HBV vaccine-induced generation of HBV reactive T and B cells could be detected regardless of their capacity to mount a serological response, indicating that patients without seroconversion are potentially protected by their HBV-reactive T cell pool.
HBV 疫苗接种被推荐用于血液透析患者，但只有 50-60%的患者出现血清转换。无论患者是否能够产生血清学反应，都可以检测到 HBV 疫苗诱导的 HBV 反应性 T 和 B 细胞的产生，这表明未发生血清转换的患者可能受到其 HBV 反应性 T 细胞库的保护。
Zotero 插件